A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Clinical trial NCT01894022 · TERMINATED
Trial details
- NCT number
- NCT01894022
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-23
- Primary completion
- 2015-11-18
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.